VISEN Pharmaceuticals Announces HK$783 Million IPO

Hong Kong – March 21, 2025 – Cooley advised VISEN Pharmaceuticals, a late-stage, near-commercialization biopharmaceutical company focused on providing treatments for select endocrine diseases in Greater China (including Hong Kong, Macau and Taiwan), on its HK$783 million (approximately US$101 million) initial public offering (IPO) on the Stock Exchange of Hong Kong, subject to the exercise of a 15% overallotment option.

VISEN offered 11,385,000 ordinary shares (subject to the overallotment option), priced at HK$68.80 per share. VISEN began trading on the Stock Exchange of Hong Kong under the stock code 2561 on March 21, 2025.

Morgan Stanley Asia Limited and Jefferies Hong Kong Limited served as joint sponsors, overall coordinators, sponsor-overall coordinators, joint global coordinators, joint bookrunners and joint lead managers for the global offering.

Partners Michael Yu, Yiming Liu and Will Cai led the Cooley team advising VISEN.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.